Drugs giant GlaxoSmithKline has joined forces with US non-profit organisation
PATH (Program for Appropriate Technology in Health) to develop its malaria
vaccine. GSK’s vaccine was 70 per cent effective in protecting people against
malaria in preliminary trials—the best result for any malaria vaccine so
far. PATH will pay GSK $6.7 million to develop it further for use in
young children, who are at highest risk of dying from malaria. GSK hopes to have
a vaccine by 2008, which it plans to distribute in Africa and other endemic
areas “at a very reasonable price”.
To continue reading, today with our introductory offers
Advertisement
More from Â鶹´«Ã½
Explore the latest news, articles and features
Life
New-to-science spider builds trap that flings ants into the air
News
Health
How menopause radically changes the brain – and what happens after
Features
Mind
‘Fusogenic’ neurosurgery let paralysed pigs walk again – are we next?
Comment
Environment
A promising natural technique to remove CO2 could backfire
News
Popular articles
Trending Â鶹´«Ã½ articles
1
We've found a mysterious substance on Titan and Pluto
2
Can prebiotics, probiotics or postbiotics help your ageing microbiome?
3
Fully autonomous drones have killed human soldiers for the first time
4
The surprising ways your brain changes from your 20s to your 40s
5
A quantum state that lasts forever may finally be within our grasp
6
Has the answer to life's origins been hiding in our cells all along?
7
New-to-science spider builds trap that flings ants into the air
8
How menopause radically changes the brain – and what happens after
9
Most portable air conditioners suck – but there's an easy fix
10
The secrets to keeping your brain sharp in old age
